- Home
- LPTX vs SMSI Comparison
LPTX vs SMSI Comparison
Compare LPTX & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- SMSI
- Stock Information
- Founded
- LPTX 2011
- SMSI 1982
- Country
- LPTX United States
- SMSI United States
- Employees
- LPTX N/A
- SMSI N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- SMSI Computer Software: Prepackaged Software
- Sector
- LPTX Health Care
- SMSI Technology
- Exchange
- LPTX Nasdaq
- SMSI Nasdaq
- Market Cap
- LPTX 14.7M
- SMSI 16.7M
- IPO Year
- LPTX N/A
- SMSI 1995
- Fundamental
- Price
- LPTX $0.35
- SMSI $0.89
- Analyst Decision
- LPTX Hold
- SMSI Strong Buy
- Analyst Count
- LPTX 1
- SMSI 1
- Target Price
- LPTX N/A
- SMSI $5.00
- AVG Volume (30 Days)
- LPTX 3.3M
- SMSI 293.0K
- Earning Date
- LPTX 08-11-2025
- SMSI 07-31-2025
- Dividend Yield
- LPTX N/A
- SMSI N/A
- EPS Growth
- LPTX N/A
- SMSI N/A
- EPS
- LPTX N/A
- SMSI N/A
- Revenue
- LPTX N/A
- SMSI $19,378,000.00
- Revenue This Year
- LPTX N/A
- SMSI $10.12
- Revenue Next Year
- LPTX N/A
- SMSI $63.12
- P/E Ratio
- LPTX N/A
- SMSI N/A
- Revenue Growth
- LPTX N/A
- SMSI N/A
- 52 Week Low
- LPTX $0.22
- SMSI $0.52
- 52 Week High
- LPTX $4.79
- SMSI $2.57
- Technical
- Relative Strength Index (RSI)
- LPTX 52.39
- SMSI 47.81
- Support Level
- LPTX $0.32
- SMSI $0.87
- Resistance Level
- LPTX $0.36
- SMSI $1.30
- Average True Range (ATR)
- LPTX 0.03
- SMSI 0.10
- MACD
- LPTX 0.01
- SMSI 0.00
- Stochastic Oscillator
- LPTX 86.94
- SMSI 20.94
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.